The Supreme Court and Biosimilars: What if it All Goes Away?
This article was originally published in RPM Report
Executive Summary
After the bruising health care reform debate in Congress, biopharmaceutical companies were comfortably on the periphery of the legal arguments playing out in the Supreme Court. But being peripheral has its disadvantages: if the Court sides with the challengers, it is possible that one of the “peripheral” provisions tossed aside will be the new biosimilars pathway. That would be a disaster for innovator companies.
You may also be interested in...
Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy
The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.
The Ascent of Abbott: Humira Marketer Battles With FDA Over Biosimilars
Abbott Labs wasn’t considered a serious biologics manufacturer when the biosimilars pathway was first being debated. But with the arthritis treatment Humira now the world’s best-selling pharmaceutical brand, the company has assumed a leadership position just as the biosimilar opportunity is emerging. And what better way to use that new role than by launching an offensive strike against FDA?
Reimbursement of Biosimilar and Biosimilar-similar ESAs
Affymax received FDA approval for the first new ESA in years. Now the company is trying to secure favorable reimbursement for its product, Omontys. The case raises the question of how CMS will treat biosimilar ESAs.